Lupin rises on expanding partnership with Eli Lilly in India

01 Dec 2016 Evaluate

Lupin is currently trading at Rs. 1527.45, up by 24.25 points or 1.61% from its previous closing of Rs. 1503.20 on the BSE.

The scrip opened at Rs. 1510.00 and has touched a high and low of Rs. 1537.00 and Rs. 1500.00 respectively. So far 45,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1911.55 on 09-Feb-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.

Last one week high and low of the scrip stood at Rs. 1545.55 and Rs. 1447.50 respectively. The current market cap of the company is Rs. 69,050.00 crore.

The promoters holding in the company stood at 46.74%, while Institutions and Non-Institutions held 41.85% and 11.41% respectively.

Pharma Major Lupin and Eli Lilly and Company (India) (Lilly) have expanded their partnership in India with the launch of Eglucent, a new brand of Lilly’s rapid-acting insulin analog Lispro. According to the agreement, Lupin will market and sell Eglucent through its own specialty field force, while Lilly will be responsible for manufacturing and import. Lilly will continue to sell Lispro under the brand name Humalog through its existing channels. Lupin had earlier collaborated with Lilly (July, 2011) to promote and distribute Lilly’s Huminsulin range of products in India and Nepal.


Eglucent is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes. Eglucent will be available in the Indian market in both, the cartridge and disposable pen form. Eglucent is a prescription drug that should be taken only when prescribed by a registered physician. It is intended as an adjunct to diet and exercise to improve the glycemic control.


Lupin is the 5th largest company in the Anti-Diabetes segment with a market share of 6.34% growing at 18% (IMS MAT September 2016). Lupin also has the distinction of being the only company in the Anti-Diabetes market with a contemporary portfolio comprising of oral anti-diabetes drugs (OAD) and injectable drugs like conventional and analog insulins. The company’s anti-diabetic portfolio contributes 11% to its India formulations sales.


Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×